Idarubicin
Appearance
![]() | |
![]() | |
Clinical data | |
---|---|
Other names | 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
AHFS/Drugs.com | Monograph |
MedlinePlus | a691004 |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 97% |
Elimination half-life | 22 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C26H27NO9 |
Molar mass | 497.494 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Idarubicin /ˌaɪdəˈruːb[invalid input: 'ɨ']sɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts [1] itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake.[2] Similar to other anthracyclines, it also induces histone eviction from chromatin.[3]
It belongs to the family of drugs called antitumor antibiotics.
It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia.
It is distributed under the trade names Zavedos (UK) and Idamycin (USA).
References
- ^ Miller JP, Stoodley RJ (2013). "Studies directed towards anthracyclinone syntheses: The use of d-glucose as a chiral auxiliary in asymmetric Diels–Alder reactions". J. Saudi Chem. Soc. 17: 29–42. doi:10.1016/j.jscs.2011.02.019.
- ^ Package insert
- ^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. doi:10.1038/ncomms2921. PMID 23715267.
External links
- Idarubicin bound to proteins in the PDB